期刊文献+

皮肤鳞状细胞癌中Axl、NF-κB的表达及意义 被引量:3

Expression of Axl and NF-κB in Cutaneous Squamous Cell Carcinoma and Its Significance
下载PDF
导出
摘要 目的观察Axl(Aexekleto)、真核转录因子-κB[NF-κB(P65)]在正常皮肤组织和皮肤鳞状细胞癌(SCC)组织中的表达情况及特点,并探讨其在皮肤SCC发生发展中可能的意义。方法采用免疫组化SABC法检测20例正常皮肤组织及40例皮肤SCC中Axl、NF-κB(P65)的表达。结果 Axl在皮肤SCC组织和正常皮肤组织中的阳性表达率分别是87.5%和0%,两者相比差异有统计学意义(χ2=42.0,P<0.05)。NF-κB(P65)在皮肤SCC组织和正常皮肤组织中阳性表达率分别为82.5%和10.0%,两者相比差异有统计学意义(χ2=28.83,P<0.05)。Axl及NF-κB(P65)在皮肤SCC中的表达等级相关系数rs=0.224,P=0.165,差异无统计学意义。结论 Axl介导的信号通路可能在皮肤SCC的发生发展过程中发挥一定的作用。 Objective To examine the expression of Axl and NF-κB(P65) in cutaneous squamous cell carcinoma (SCC) and normal skin tissues and its significance in the development of SCC. Methods Expression of Axl and NF-κB(P65) was immunohistochemically detected in 40 SCC tissues and 20 normal skin tissues. Results The positive expression rate of Axl was 87.5 % in SCC tissues and 0% in normal skin tissues and there was a significant difference (P〈0.05). The positive expression rate of NF-κB(P65) was 82.5% and 10.0% in the two groups,respectively (P〈0.05). No correlation between Axl and NF-κB(P65) was found in SCC tissues. Conclusion The aberrant over-expression of Axi and NF-κB may play an important role in the occurrence and develooment of SCC.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2013年第5期569-572,共4页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
关键词 AXL 真核转录因子-κB 皮肤鳞状细胞癌 Axl NF-κB(P65) cutaneous squamous cell carcinoma
  • 相关文献

参考文献21

  • 1王侠生;廖康煌;杨国亮.皮肤病学[M]上海:上海科学技术出版社,2005978-979.
  • 2Rowe D E,Carroll R J,Day C L Jr. Prognostic factors for local recurrence,metastasis,and survival rates in squamous cell carcinoma of the skin,ear,and lip.Implications for treatment modality selection[J].Journal of the American Academy of Dermatology,1992,(06):976-990.
  • 3Veness M J. Time to rethink TNM staging in cutaneous SCC[J].Lancet Oncology,2008,(08):702-703.
  • 4Holland S J,Pan A,Franci C. R428,a selective small molecule inhibitor of Axl kinase,blocks tumor spread and prolongs survival in models of metastatic breast cancer[J].Cancer Research,2010,(04):1544-1554.
  • 5Song X,Wang H,Logsdon C D. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma[J].Cancer,2011,(04):734-743.
  • 6Liu R,Gong M,Li X. Induction,regulation,and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma[J].Blood,2010,(02):297-305.
  • 7Hanahan D,Weinberg R A. The hallmarks of cancer[J].Cell,2000,(01):57-70.
  • 8Prasad D,Rothlin C V,Burrola P,et at. TAM receptor function in the retinal pigment epithelium[J].Molecular and Cellular Neuroscience,2006,(01):96-108.doi:10.1016/j.mcn.2006.06.011.
  • 9Xiong W,Chen Y,Wang H,et at. Gas6 and the Tyro-3 receptor tyrosine kinase subfamily regulate the phagocytic function of Sertoli cells[J].Reproduction,2008,(01):77-87.doi:10.1530/REP-07-0287.
  • 10Chen Y,Wang H,Qi N,et at. Functions of TAM RTKs in regulating spermatogenesis and male fertility in mice[J].Reproduction,2009,(04):655-666.doi:10.1530/REP-09-0101.

二级参考文献54

  • 1刘亦晴,张建文,陈奎生,翟晓梅.皮肤鳞状细胞癌和基底细胞癌组织中缺氧诱导因子-1α、血管内皮生长因子的表达[J].郑州大学学报(医学版),2007,42(2):340-342. 被引量:7
  • 2Choo MK, Sakurai H, Kim DH, et al. A ginseng saponin metabolite suppresses tumor necrosis factor - alpha - promoted metastasis by suppressing nuclear factor - kappaB signaling in murine colon cancer cells [ J ]. Oncol Rep, 2008, 19(3) :595 -600.
  • 3Al - Dissi AN, Haines DM, Singh B, et al. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squa- mous cell carcinomas and trichoepitheliomas [ J ]. Vet Pathol, 2007,44 (6) : 823 - 830.
  • 4Lee SO, Jeong Y J, Kim M, et al. Suppression of PMA - induced tumor cell invasion by capillarisin via the inhibition of NF - kappaB - dependent MMP - 9 expression [J]. Biochem Biophys Res Commun, 2008, 366(4): 1019 - 1024.
  • 5Tamatani T, Azuma M, Ashida Y, et al. Enhanced radiosensitization and chemosensitization in NF -kappaB - suppressed human oral cancer cells via the inhibition of gamma - irradiation - and 5 - FU - induced production of IL - 6 and IL - 8 [ J ]. Int J Cancer, 2004,108 (6) : 912 - 921.
  • 6Djordjevic G, Matusan - Ilijas K, Sinozic E, et al. Relationship between vascular endothelial growth factor and nuclear factor - kappaB in renal cell tumors [ J ]. Croat Med J, 2008,49(5) :608 -617.
  • 7Shibata A, Nagaya T, Imai T, et al. Inhibition of NF- kappa B activity decreases the VEGF mRNA expression in MDA - MB - 231 breast cancer cells [ J]. Breast Cancer Res Treat, 2002,73 (3) :237 - 243.
  • 8Yoshimura T,Oppenheim J J.Chemerin reveals its chemeric nature[J].J Exp Med,2008,205(10):2187-2190.
  • 9Choudhury R P,Lee J M,Greaves D R.Mechanisms of disease:macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis[J].Nat Clin Pract Cardiovasc Med,2005,2(6):309-315.
  • 10Owen J S.Role of ABC1 gene in cholesterol efflux and atheroprotection[J].Lancet,1999,354(9188):1402-1403.

共引文献16

同被引文献27

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,2006,6(1):4.
  • 2Golsteyn R M, Schultz S J, Bartek J, et al. Cell cycle analysis and chromosomal localization of human Plkl,a putative hom- ologue of the mitotic kinases Drosophila polo and Saceharo- myces cerevisiae Cdc5[J]. J Cell Sci, 1994,107(Pt 6) : 1509- 1517.
  • 3van de Weerdt B C,Medema R H. Polo-like kinases..a team in control of the division[J]. Cell Cycle, 2006,5 (8) : 853-864.
  • 4Degenhardt Y, Lampkin T. Targeting Polo-like kinase in canc- er therapy[J]. Clin Cancer Res,2010,16(2) :384-389.
  • 5Rizki A,Mott J D,Bissell M J. Polo-like kinase 1 is involved in invasion through extracellular matrix [J]. Cancer Res, 2007,67(23) : 11106-11110.
  • 6Chopra P,Sethi G,Dastidar S G,et al. Polo-like kinase inhibi- tors,an emerging opportunity for cancer therapeutics[J]. Ex-pert Opin Investig Drugs,2010,19(1):27-43.
  • 7King S I, Purdie C A, Bray S E, et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1)in primary breast canc- er is associated with TP53 mutation and poor clinical outcom [J]. Breast Cancer Res, 2012,14(2) : R40.
  • 8Schmit T L, Zhong W, NihaJ M, et al. Polo-like kinase 1 (Plkl)in non-melanoma skin cancers[J]. Cell Cycle, 2009,8 (17) :2697-2702.
  • 9Indovina P, Marcelli E, Casini N, et al. Emerging roles of RB family: new defense mechanisms against tumor progression [J]. J Cell Physiol, 2013,228(3) : 525-535.
  • 10Poznic M. Retinoblastoma protein:a central processing unit [J]. J Biosci, 2009,34 (2) : 305-312.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部